Salvage treatment with apatinib for advanced non-small cell lung cancer
Objective:No definitive chemotherapeutic regimen has been established in patients with non-small cell lung cancer(NSCLC)who failed from prior second or third-line treatment.The aim of this study was to evaluate the feasibility and safety of apatinib,a VEGFR-2 inhibitor,in advanced NSCLC as salvage treatment.Methods:We evaluated the efficacy and toxicity of apatinib as salvage therapy in patients with previously treated advanced NSCLC from 2014 to 2015 in Zhejiang Cancer Hospital.Survival analysis was evaluated by Kaplan-Meier method.Results:Forty two patients were included in current study.Four patients achieved partial response,and twenty-two achieved stable disease,representing a response rate of 9.5%and disease control rate of 61.9%.Median progression-free survival and overall survival were 4.2 and 6.0 months,respectively.The toxicities associated with the apatinib was generally acceptable with a totally grade 3/4 toxicity of 50%.Conclusion:Apatinib appears to have some activity against advanced NSCLC as salvage treatment.
Non-small cell lung cancer apatinib salvage chemotherapy efficacy toxicity Introduction
宋正波 张沂平
浙江省肿瘤医院胸部肿瘤内科 310022
国内会议
合肥
英文
1-9
2017-06-15（万方平台首次上网日期，不代表论文的发表时间）